Irritable bowel syndrome. Irritable bowel syndrome
Conditions
Interventions
Intervention 1: Intervention group: Daily 50-200 milligram Sertraline manufactured in Doctor Abidi Pharmaceutical Company and 200 milligram Clofac for eight weeks. Intervention 2: Control group: Daily
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The presence of ROME III diagnostic criteria for the diagnosis of irritable bowel syndrome Written consent for participation in the study
Exclusion criteria
Exclusion criteria: Age under 18 years Allergy to sertraline The presence of warning signs such as chronic fever, weight loss, gastrointestinal bleeding Pregnancy and breast feeding Use of any drug that affects the bowel function (such as laxatives, anti diarrhea and antibiotics) within one month before entering the study Known cases of lactose intolerance Comorbidity of other serious physical or psychological illnesses, serious suicidal thoughts and substance dependence that affect the treatment of patients and their compliance with the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of irritable bowel syndrome symptoms. Timepoint: At baseline, and the fourth and eighth weeks after the intervention. Method of measurement: Visual Analogue Scale (VAS).;The patients quality of life. Timepoint: At baseline, and the eighth week after the intervention. Method of measurement: SF-36 quality of life questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug side effects. Timepoint: The fourth and eighth weeks after the intervention. Method of measurement: Medical visit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSussan Moudi, MD
Babol University of Medical Sciences
Outcome results
None listed